Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iXensor CoROCO:6734 +0.36%48 Debt-to-Equity is 3.20 as of Jun. 2026, which is 4471% above its 10-year median of 0.07. GuruFocus rates ROCO:6734 with a GF Score™ of 48/100 and a GF Value™ of NT$5.38 (Fairly Valued). The stock has 5 warning signs investors should review. Among 698 Medical Devices & Instruments companies, iXensor Co ranks worse than 96.7% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for iXensor Co's Debt-to-Equity or its related term are showing as below:
ROCO:6734'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.64 Med: 0.07 Max: 3.77
Current: 3.2
During the past 10 years, the highest Debt-to-Equity Ratio of iXensor Co was 3.77. The lowest was -3.64. And the median was 0.07.
ROCO:6734's Debt-to-Equity is ranked worse than 96.7% of 698
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs ROCO:6734: 3.20
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
iXensor Co Debt-to-Equity Related Terms
iXensor Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for iXensor Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6734 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, iXensor Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iXensor Co Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iXensor Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where iXensor Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iXensor Co (ROCO:6734) has a Debt-to-Equity of 3.20 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on iXensor Co and its competitors. This is 4471% above median its historical median of 0.07. According to the industry distribution chart, iXensor Co ranks #675 out of 698 companies in the Medical Devices & Instruments industry, placing it in the top 96.7%.
Is iXensor Co's Debt-to-Equity too high?
iXensor Co's current Debt-to-Equity of 3.20 is 4471% above median its 10-year median of 0.07. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. iXensor Co's value of 3.20 is 1233.3% above this industry median. Based on the distribution chart, iXensor Co ranks #675 out of 698 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iXensor Co has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does iXensor Co's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, iXensor Co ranks #675 out of 698 companies for Debt-to-Equity. This places iXensor Co in the lower half of its industry. The industry median Debt-to-Equity is 0.24. iXensor Co's value of 3.20 is 1233.3% above this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.24, iXensor Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iXensor Co's current Debt-to-Equity of 3.20 is 1233.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on iXensor Co and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iXensor Co's current Debt-to-Equity is 3.20, which is 4471% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iXensor Co stock overvalued right now?
Based on GuruFocus' analysis, iXensor Co (ROCO:6734) is currently considered Fairly Valued. The stock's GF Value™ is NT$5.38, compared to a current price of NT$5.62 — trading 4.5% above its estimated fair value. The current Debt-to-Equity is 3.20, which is 4471% above median its 10-year median of 0.07 and 1233.3% above the Medical Devices & Instruments industry median of 0.24. iXensor Co's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For iXensor Co (ROCO:6734), the current Debt-to-Equity is 3.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iXensor Co (ROCO:6734) Overvalued in 2026?
Based on GuruFocus' analysis, iXensor Co stock appears to be overvalued.
The current stock price of NT$5.62 is trading 4.5% above its estimated GF Value™ of NT$5.38.
GuruFocus considers iXensor Co to be Fairly Valued.
Key valuation signals for ROCO:6734:
Debt-to-Equity: 3.20 (4471% above median its 10-year median of 0.07)
GF Value™: NT$5.38 vs. price of NT$5.62 (4.5% above fair value)
Industry Position: 1233.3% above the Medical Devices & Instruments median (#675 of 698)
No single metric tells the full story. See the ROCO:6734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iXensor Co Ltd is a Taiwan based company involved in research and development, manufacturing and sales of medical equipment. Its PixoTest technology utilizes the lighting and image sensing module of the smartphone or mobile device to detect the color change reaction on the biochemical test strip. This enables the users to monitor their conditions of diabetes, cardiovascular diseases, women health problems, or infectious diseases.
48GF Score
Get the complete analysis for ROCO:6734
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6734 has been successfully added to your 
